Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction

Human dose‐prediction is fundamental for ranking lead‐optimization compounds in drug discovery and to inform design of early clinical trials. This tutorial describes how uncertainty in such predictions can be quantified and efficiently communicated to facilitate decision‐making. Using three drug‐discovery case studies, we show how several uncertain pieces of input information can be integrated into one single uncomplicated plot with key predictions, including their uncertainties, for many compounds or for many scenarios, or both.

[1]  A. Stevens Industrial perspective. , 2000, Ultrasound in medicine & biology.

[2]  U. Fagerholm Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance , 2007, The Journal of pharmacy and pharmacology.

[3]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[4]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[5]  G. Meno-Tetang,et al.  On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. , 2005, Basic & clinical pharmacology & toxicology.

[6]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.

[7]  R C Chou,et al.  Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.

[8]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.

[9]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.

[10]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[11]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[12]  Detlof von Winterfeldt,et al.  Bridging the gap between science and decision making , 2013, Proceedings of the National Academy of Sciences.

[13]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[14]  T Lavé,et al.  Challenges and opportunities with modelling and simulation in drug discovery and drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  Baruch Fischhoff,et al.  The sciences of science communication , 2013, Proceedings of the National Academy of Sciences.

[16]  Mitchell J. Small,et al.  Best Practice Approaches for Characterizing, Communicating, and Incorporating Scientific Uncertainty in Decision Making , 2009 .

[17]  George Loizou,et al.  Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[19]  Douglas Ferguson,et al.  Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  Yifeng Lu,et al.  Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans , 2011, The AAPS Journal.

[21]  Harold Boxenbaum,et al.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  S. Stegemann,et al.  When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  Hyunyoung Jeong,et al.  Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.

[24]  M. Aitken Species differences in pharmacodynamics: Some examples , 1983, Veterinary Research Communications.

[25]  T Lavé,et al.  Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.

[26]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. , 2011, Journal of pharmaceutical sciences.

[27]  Michael Mayersohn,et al.  A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. , 2006, Journal of pharmaceutical sciences.

[28]  White House,et al.  U.S. Climate Change Science Program , 2009 .

[29]  Malcolm Rowland,et al.  Uncertainty Analysis in Pharmacokinetics and Pharmacodynamics: Application to Naratriptan , 2005, Pharmaceutical Research.

[30]  V. Aloyo,et al.  Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice , 2011, Psychopharmacology.

[31]  Kiyomi Ito,et al.  Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.

[32]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[33]  K. Hole,et al.  Morphine induces aggression but not analgesia in the naked mole-rat (Heterocephalus glaber). , 1990, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[34]  Michael Gertz,et al.  Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.

[35]  B. Fischhoff,et al.  The role of social and decision sciences in communicating uncertain climate risks , 2011 .

[36]  D. Smith Pharmacokinetics and pharmacodynamics in toxicology. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  Radhey S. Gupta,et al.  Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis) , 1986, Journal of cellular physiology.

[38]  Huadong Tang,et al.  A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING , 2005, Drug Metabolism and Disposition.

[39]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[40]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[41]  Bill J Smith,et al.  Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches , 2009, Journal of clinical pharmacology.

[42]  J. McNeill,et al.  To scale or not to scale: the principles of dose extrapolation , 2009, British journal of pharmacology.

[43]  Gregory F Ball,et al.  Species Differences in the Relative Densities of D1- and D2-Like Dopamine Receptor Subtypes in the Japanese Quail and Rats: An in vitro Quantitative Receptor Autoradiography Study , 2009, Brain, Behavior and Evolution.

[44]  Shobha Bhattachar,et al.  The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.

[45]  Christian P Karger,et al.  A method to visualize the uncertainty of the prediction of radiobiological models. , 2013, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[46]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[47]  Yuichi Sugiyama,et al.  Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[48]  Lawrence X. Yu,et al.  Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation , 2012, AAPS Journal.

[49]  I. Mahmood Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). , 2006, Journal of pharmaceutical sciences.

[50]  W. Hayton,et al.  Allometric scaling of xenobiotic clearance: Uncertainty versus universality , 2008, AAPS PharmSci.

[51]  Tufve Nyholm,et al.  Evaluation of uncertainty predictions and dose output for model-based dose calculations for megavoltage photon beams. , 2006, Medical physics.

[52]  Susan Joy Hassol,et al.  Communicating the science of climate change , 2011 .

[53]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[54]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[55]  U. Fagerholm,et al.  Prediction of human pharmacokinetics – evaluation of methods for prediction of volume of distribution , 2007, The Journal of pharmacy and pharmacology.

[56]  R. Obach,et al.  DMD054031 1975..1993 , 2013 .

[57]  Mike Pearson,et al.  Visualizing Uncertainty About the Future , 2022 .

[58]  I. Nestorov,et al.  Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. , 2001, Toxicology letters.

[59]  David V. Budescu,et al.  Improving Communication of Uncertainty in the Reports of the Intergovernmental Panel on Climate Change , 2009, Psychological science.

[60]  Peter Gennemark,et al.  Automated analysis of routinely generated preclinical pharmacokinetic and pharmacodynamic data , 2014, J. Bioinform. Comput. Biol..

[61]  Y. Sugiyama,et al.  Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. , 2003, Drug metabolism and pharmacokinetics.

[62]  Andrew Hughes,et al.  Model-based drug discovery: implementation and impact. , 2013, Drug discovery today.

[63]  Erik Sjögren,et al.  In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[64]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[65]  Talia Flanagan,et al.  In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[66]  Y. Huh,et al.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[67]  Patrick Poulin,et al.  Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches , 2012, The AAPS Journal.

[68]  Johan Gabrielsson,et al.  A modeling approach for compounds affecting body composition , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[69]  Philip Campbell,et al.  Understanding the receivers and the reception of science's uncertain messages , 2011, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[70]  Riemannian Manifolds,et al.  SOME EXAMPLES OF , 1984 .

[71]  James H. Brown,et al.  A General Model for the Origin of Allometric Scaling Laws in Biology , 1997, Science.